1887

Chapter 2 : Mechanisms of Quinolone Action

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Preview this chapter:
Zoom in
Zoomout

Mechanisms of Quinolone Action, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555817817/9781555812317_Chap02-1.gif /docserver/preview/fulltext/10.1128/9781555817817/9781555812317_Chap02-2.gif

Abstract:

This chapter introduces the quinolones with a brief consideration of DNA topoisomerases and quinolone target preference. Throughout the chapter attention is given to fluoroquinolone structure. Recently discovered examples include the relaxation of supercoils associated with infection of cultured macrophages by serovar Typhimurium and with hydrogen peroxide treatment of . The bacterial topoisomerases are divided into three groups: type I (topoisomerases I and III), type II (gyrase and topoisomerase IV), and specialized topoisomerases (enzymes that catalyze transposition or integration/excision of bacteriophage DNA from the bacterial chromosome). A function of topoisomerase I is the topological destabilization of transcription-mediated R loops. Another is likely to be control of global supercoiling, since a defect that raises supercoiling also suppresses a mutation, a defect that has a global effect on chromosome condensation. Quinolone binding to these mutant gyrase-DNA complexes induces a conformational change that can be detected in the GyrB subunit by limited proteolysis. The location of the quinolone-gyrase-DNA complexes on the bacterial chromosome is likely to influence the potential damage that quinolones can cause. The bacteriostatic effects of the quinolones are now understood at a level sufficient to allow structure-function interpretations. From a clinical perspective, there is a need to identify safe compounds that rapidly kill bacteria, especially resistant mutants. However, further refinement could become an academic exercise if ways are not developed to slow the emergence of fluoroquinolone-resistant pathogens.

Citation: Drlica K, Hooper D. 2003. Mechanisms of Quinolone Action, p 19-40. In Hooper D, Rubinstein E (ed), Quinolone Antimicrobial Agents, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555817817.ch2
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

Figures

Image of Figure 1
Figure 1

Structures of commonly studied fluroquinolones.

Citation: Drlica K, Hooper D. 2003. Mechanisms of Quinolone Action, p 19-40. In Hooper D, Rubinstein E (ed), Quinolone Antimicrobial Agents, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555817817.ch2
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 2
Figure 2

Model of supercoiling and relaxation by DNA gyrase. (a) The 43-kDa and 47-kDa regions of GyrB, along with the 64-kDa region of GyrA are shown as a tetramer. The 33-kDa C-terminal domains of GyrA are omitted for clarity, as is the DNA wrap around gyrase. Supercoiling occurs when gyrase either binds a G segment of DNA (a) or assembles onto the G segment (b). The resulting complex (c) is a substrate for quinolone binding. The ternary complex (c) cleaves DNA to form a cleavage complex (d). ATP binds to the 43-kDa domains of GyrB, causing them to close and capture the T segment of DNA (e). The T segment is transported through the break in the G segment and into the bottom cavity of gyrase (f). The break in the G segment is religated (g), and the T segment is then released from the bottom cavity through the exit gate in the enzyme (h). The exit gate closes, resetting the enzyme for a new round of supercoiling. Between capture of the T segment and resetting of the enzyme, ATP is hydrolyzed and released. The figure was provided by Dr. J. G. Heddle (John Innes Centre, Norwich, United Kingdom). Reprinted from reference 83 by courtesy of Marcel Dekker, Inc.

Citation: Drlica K, Hooper D. 2003. Mechanisms of Quinolone Action, p 19-40. In Hooper D, Rubinstein E (ed), Quinolone Antimicrobial Agents, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555817817.ch2
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 3
Figure 3

Structure of DNA gyrase GyrA59 dimer. The figure shows a ribbon representation (generated in RasMol) of the GyrA59 fragment ( ), courtesy of J.G. Heddle (John Innes Centre). The upper panel shows the entire GyrA59 dimer while the lower panel is an enlargement of the boxed region in the upper panel. Amino acids that change to confer quinolone resistance are indicated in black and by the amino acid numbers. Amino acid 51 is in helix 2, amino acid 67 is in helix 3, and amino acids 83 and 87 are in helix 4. The figure was adapted from reference 61. Arrows in the upper panel indicate the location of changes that increase illegitimate recombination and spontaneous induction of lambda prophage as described in reference 7.

Citation: Drlica K, Hooper D. 2003. Mechanisms of Quinolone Action, p 19-40. In Hooper D, Rubinstein E (ed), Quinolone Antimicrobial Agents, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555817817.ch2
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 4
Figure 4

Proposed quinolone binding site. Orientation of fluoroquinolones and GyrA oc-helix-4. a-Helix-4, adapted from the crystal structure of the breakage-reunion domain of the GyrA protein of ( ), is drawn parallel to the long axis of the fluoroquinolone. For clarity, amino acid numbers represent positions in the GyrA protein. (The experiments were performed with position 81 in the figure corresponds to 89 in Arrows indicate positions of an ethyl group that changes the identity of the most resistant mutant (see text). The figure was adapted from reference 150.

Citation: Drlica K, Hooper D. 2003. Mechanisms of Quinolone Action, p 19-40. In Hooper D, Rubinstein E (ed), Quinolone Antimicrobial Agents, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555817817.ch2
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 5
Figure 5

Effect of GyrA variation on susceptibility to fluoroquinolones. MIC was determined for two structurally similar fluoroquinolones with the indicated fluoroquinolone-resistant mutants of . (The changes in the GyrA variants are indicated by standard amino acid abbreviations with the letter preceeding the number indicating the wild-type amino acid and the letter following the number representing the variant; the numbers used correspond to those shown in Fig. 4 and represent positions numbered according to the GyrA protein.) Panel A utilized fluoroquinolone PD161144, which has an ethyl group attached to the C-7 ring nitrogen as indicated by an arrow in Fig. 4 . Panel B utilized fluoroquinolone PD161148, which has its ethyl group attached to a C-7 ring carbon adjacent to the nitrogen indicated in Fig. 4 . The figure was adapted from data presented in reference 150.

Citation: Drlica K, Hooper D. 2003. Mechanisms of Quinolone Action, p 19-40. In Hooper D, Rubinstein E (ed), Quinolone Antimicrobial Agents, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555817817.ch2
Permissions and Reprints Request Permissions
Download as Powerpoint

References

/content/book/10.1128/9781555817817.chap2
1. Ali, J ., , A. Jackson,, A. Howells,, and A. Maxwell. 1993. The43-kDa N-terminal fragment of the gyrase B protein hydrolysesATP and binds coumarin drugs. Biochemistry 32: 2717 2724.
2. Ali, J . A.,, G. Orphanides,, and A. Maxwell. 1995. Nucleotidebinding to the 43-kilodalton N-terminal fragment of theDNA gyrase. Biochemistry 34: 9801 9808.
3. Alovero, F.,, X.-S. Pan,, J . Morris,, R. Manzo,, and L. Fisher. 1999. Engineering the specificity of antibacterial fluoroquinolones:benzenesulfonamide modifications at C-7 ofciprofloxacin change its primary target in Streptococcus pneumoniae from topoisomerase IV to gyrase. Antimicrob.Agents Chemother. 44: 320 325.
4. Anderson, V.,, T. Gootz,, and N. Osheroff. 1998. Topoisomerase IV catalysis and the mechanism of quinoloneaction.J. Biol. Chem. 274: 17879 17885.
5. Anderson, V.,, R. Zaniewski,, F. Raczmarek,, T. Gootz,,and N. Osheroff. 2000. Action of quinolones against Staphylococcus aureus topoisomerase IV; basis for DNAcleavage enhancement. Biochemistry 39: 2726 2732.
6. Anderson, V. E.,, R. P. Zaniewski,, F. S. Kaczmarek,, T. D. Gootz,, and N. Osheroff. 1999. Quinolones inhibit DNAreligation mediated by Staphylococcus aureus topoisomeraseIV. J. Biol. Chem. 274: 35927 35932.
7. Ashizawa, Y.,, T. Yokochi,, Y. Ogata,, Y. Shobuike,, J . Kato,,and H. Ikeda. 1999. Mechanism of DNA gyrase-mediatedillegitimate recombination: characterization of Escherichiacoli gyrA mutants that confer hyper-recombination phenotype. J.Mol. Biol. 289: 447 458.
8. Bachellier, S.,, D. Perrin,, M. Hoffnung,, and E. Gilson. 1993. Bacterial interspersed mosaic elements (BIMEs) are presentin the genome of Klebsiella . Mol. Microbiol. 7: 537 544.
9. Bachellier, S.,, W. Saurin,, D. Perrin,, M. Homung,, and E. Gilson. 1994. Structural and functional diversity amongbacterial interspersed mosaic elements (BIMEs). Mol.Microbiol. 12: 61 70.
10. Bahng, S.,, E. Mossessova,, P. Nurse,, and K. Marians. 2000. Mutational analysis of Eshcerichia coli topoisomerase IV. J. Biol. Chem. 275: 4112 4117.
11. Baird, C. L.,, T. T. Harkins,, S. K. Morris,, and J . E. Lindsley. 1999. Topoisomerase II drives DNA transport by hydrolyzingone ATP. Proc. Natl. Acad. Sci. USA 96: 13685 13690.
12. Barnard, F.,, and A. Maxwell. 2001. Interaction betweenDNAgyrase and quinolones: the effect of alanine mutationsat A subunit residues Ser-83 andAsp-87. Antimicrob.Agents Chemother. 45: 1994 2000.
13. Bendich, A. 2001. The form of DNA molecules in bacterialcells. Biochimie 83: 177 186.
14. Berardini, M.,, P. L. Foster,, and E. L. Loechler. 1999. DNApolymerase II (polB) is involved in a new DNA repair pathwayfor DNA interstrand cross-links in Escherichia coli . J.Bacteriol. 181: 2878 2882.
15. Berger, J . M.,, S. J . Gamblin,, S. C. Harrison,, and J . C. Wang. 1996. Structure and mechanism of DNA topoisomerase II. Nature 379: 225 232.
16. Blanche, F.,, B. Cameron,, F.-X. Bernard,, L. Maton,, B. Manse,, L. Ferrero,, N. Ratet,, C. Lecoq,, A. Goniot,, D. Bisch,,and J. Crouzet. 1996. Differential behaviors of Staphylococcus aureus and Escherichia coli type II DNAtopoisomerases. Antimicrob. Agents Chemother. 40: 2714 2720.
17. Boccard, F.,, and P. Prentki. 1993. Specific interaction of IHF with RIBs, a class of bacterial repetitive DNA elements located at the 39 end of transcription units. EMBO J. 12: 5019 5027.
18. Breines, D. M.,, S. Ouabdesselam,, E. Y. Ng,, J . Tankovic,, S. Shah,, C. J . Soussy,, and D. C. Hooper. 1997. Quinolone resistance locus nfxD of Escherichia coli is a mutant allele of the parE gene encoding a subunit of topoisomerase IV. Antimicrob. Agents Chemother. 41: 175 179.
19. Broccoli, S.,, P. Phoenix,, and M. Drolet. 2000. Isolation of the topB gene encoding DNA topoisomerase III as a multicopysuppressor of top A null mutations in Escherichia coli . Mol. Microbiol. 35: 58 68.
20. Burden, D. A.,, and N. Osheroff. 1999. In vitro evolution of preferred topoisomerase II DNA cleavage sites. J. Biol.Chem. 274: 5227 5235.
21. Cambau, E.,, F. Borden,, E. Collatz,, and L. Gutmann. 1993. Novel gyrA point mutation in a strain of Escherichia coli resistant to fluoroquinolones but not to nalidixic acid. Antimicrob. Agents Chemother. 37: 1247 1252.
22. Champoux, J . J . 2001. DNA topoisomerases: structure, function,and mechanism. Annu. Rev. Biochem. 70: 369 413.
23. Champoux, J .J ., , and M. D. Been,. 1980. Topoisomerasesand theswivel problem, p. 809 815. In B. Alberts(ed.), Mechanistic Studies of DNA Replication and GeneticRecombination: ICN-UCLA Symposia onMolecular andCellular Biology. Academic Press, New York, N.Y.
24. Changela, A.,, R. DiGate,, and A. Mondragon. 2001. Crystalstructure of a complex of a type 1A DNA topoisomerasewith a single-stranded DNA molecule. Nature 411: 1077 1081.
25. Chen, C.-R.,, M. Malik,, M. Snyder,, and K. Drlica. 1996. DNA gyrase and topoisomerase IV on the bacterial chromosome:quinolone-induced DNA cleavage. J . Mol. Biol. 258: 627 637.
26. Chow, R.,, T. Dougherty,, H. Fraimow,, E. Bellin,, and M. Miller. 1988. Association between early inhibition of DNAsynthesis and the MICs and MBCs of carboxyquinoloneantimicrobial agents for wild-type and mutant [gyrAnfxB(ompF) acrA] Escherichia coli K-12. Antimicrob.Agents Chemother. 32: 1113 1118.
27. Cole, S. T.,, R. Brosch,, J . Parkhill,, T. Gamier,, C. Churcher,, D. Harris,, S. Gordon,, K. Eiglmeier,, S. Gas,, C. E. Barry,, F. Tekaia,, K. Babcock,, D. Basham,, D. Brown,, T. Chillingworth,, R. Connor,, R. Davies,, K. Devlin,, T. Feltwell,, S. Gentles,, N. Hamlin,, S. Holroyd,, T. Hornsby,, K. Jagels,,and B. Barrell. 1998. Deciphering the biology of Mycobacteriumtuberculosis from the complete genome sequence. Nature 393: 537 544.
28. Condemine, G.,, and C. Smith. 1990. Transcription regulatesoxolinic acid-induced DNA gyrase cleavage at specific sites onthe E. coli chromosome. Nucleic Acids Res. 18: 7389 7395.
29. Cook, T. M.,, W. Deitz,, and W. Goss. 1966. Mechanism ofaction of nalidixic acid on Escherichia coli . J. Bacteriol. 91: 774 779.
30. Crisona, N.,, T. Strick,, D. Bensimon,, V. Croquette,, and N. Cozzarelli. 2000. Preferential relaxation of positively supercoiledDNA by E. coli topoisomerase IV in single-moleculeand ensemble measurements. Genes Dev. 14: 2881 2892.
31. Critchlow, S. E.,, and A. Maxwell. 1996. DNA cleavage isnot required for the binding of quinolone drugs to the DNAgyrase-DNA complex. Biochemistry 35: 7387 7393.
32. Crumplin, G.,, M. Kenwright,, and T. Hirst. 1984. Investigations into the mechanism of action of the antibacterialagent norfloxacin. J. Antimicrob. Chemother. 13: 9 23.
33. Crumplin, G. C.,, and J. T. Smith. 1975. Nalidixic acid: anantibacterial paradox. Antimicrob. Agents Chemother. 8: 251 261.
34. Cullen, M.,, A. Wyke,, R. Kuroda,, and L. Fisher. 1989. Cloning and characterization of a DNA gyrase A gene from Escherichia coli that confers clinical resistance to 4-quinolones. Antimicrob. Agents Chemother. 33: 886 894.
35. Dasgupta, S.,, S. Maisnier-Patin,, and K. Nordstrom. 2000. New genes with old modus operandi . EMBO Rep. 1: 323 327.
36. Dean, F.,, M. Krasnow,, R. Otter,, M. Matzuk,, S. Spengler,,and N. Cozzarelli. 1983. Escherichia coli type I topoisomerases:identification, mechanism and role in recombination. Cold Spring Harbor Symp. Quant. Biol. 47: 769 777.
37. Deitz, W.H.,, T. M. Cook,, and W. A. Goss. 1966. Mechanismof action of nalidixic acid on Escherichia coli. HI. Conditionsrequired for lethality. J .Bacteriol. 91: 768 773.
38. DiGate, R.,, and K. Marians. 1988. Identification of a potentdecatenating enzyme from Escherichia coli . J. Biol. Chem. 263: 13366 13373.
39. DiGate, R.,, and K. Marians. 1989. Molecular cloning andDNA sequence analysis of Escherichia coli topB, the geneencoding topoisomerase Jr. J. Biol. Chem. 264: 17924 17930.
40. DiGate, R.,, and K. Marians. 1992. Escherichiacoli topoisomeraseIll-catalyzed cleavage of RNA. J. Biol. Chem. 267: 20532 20535.
41. DiNardo, S.,, K. Voelkel,, R. Sternglanz,, A. Reynolds,, and A. Wright. 1982. Esherichia coli DNA topoisomerase Imutants have compensatory mutations in DNA gyrasegenes. Cell 31: 43 51.
42. Discotto, L. F.,, L. Lawrence,, K. Denbleyker,, and J . F. Barrett. 2001. Staphylococcus aureus mutants selected by BMS-284756. Antimicrob. Agents Chemther. 45: 3273 3275.
43. Dong, Y.,, C. Xu,, X. Zhao,, J . Domagala,, and K. Drlica. 1998. Fluoroquinolone action against mycobacteria: effectsof C8 substituents on bacterial growth, survival, and resistance. Antimicrob. Agents Chemother. 42: 2978 2984.
44. Dorman, C.,, G. Barr,, N. NiBhriain,, and C. Higgins. 1988. DNA supercoiling and the anaerobic growth phase regulationof tonB gene expression. J. Bacteriol. 170: 2816 2826.
45. Drlica, K. 1992. Control of bacterial DNA supercoiling. Mol. Microbiol. 6: 425 433.
46. Drlica, K.,, R. Franco,, and T. Steck. 1988. Rifampicin and rpoB mutations can alter DNA supercoiling in Escherichiacoli . J. Bacteriol. 170: 4983 4985.
47. Drlica, K.,, S. H. Manes,, and E. C. Engle. 1980. DNA gyraseon the bacterial chromosome: possibility of two levels ofaction. Proc. Natl. Acad. Sci. USA 77: 6879 6883.
48. Drlica, K.,, and M. Snyder. 1978. Superhelical Escherichiacoli DNA: relaxation by coumermycin. J. Mol. Biol. 120: 145 154.
49. Drlica, K.,, and X . Zhao. 1997. DNA gyrase, topoisomeraseIV, and the 4-quinolones. Microbiol. Mol. Biol. Rev. 61: 377 392.
50. Drolet, M.,, P. Phoenix,, R. Menzel,, E. Masse,, L. F. Liu, andR. J . Crouch. 1995. Overexpression of RNase H partiallycomplements the growth defect of an Escherichia coli Atop A mutant: R-loop formation is a major problem in the absenceof DNA topoisomerase I. Proc. Natl. Acad. Sci. USA 92: 3526 3530.
51. Earnshaw, W. C.,, B. Halligan,, C. A. Cooke,, M. M. S. Heck,,and L. F. Liu. 1985. Topoisomerase II is a structural componentof mitotic chromosome scaffolds. J. Cell Biol. 100: 1706 1715.
52. Espeli, O.,, and F. Boccard. 1997. In vivo cleavage of Escherichia coli BIME-2 repeats by DNA gyrase: geneticcharacterization of the target and identification of the cut site. Mol. Microbiol. 26: 767 777.
53. Fass, D.,, C. E. Bogden,, and J . M. Berger. 1999. Quaternary changes in topoisomerase II may direct orthogonal movement of two DNA strands. Nat. Struct. Biol. 6: 322 326.
54. Ferrero, L.,, B. Cameron,, and J . Crouzet. 1995. Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin resistant mutants of Staphylococcus aureus . Antimicrob.Agents Chemother. 39: 1554 1558.
55. Ferrero, L.,, B. Cameron,, B. Manse,, D. Lagneaux,, J . Crouzet,, A. Famechon,, and F. Blanche. 1994. Cloning and primary structure of Staphylococcus aureus DNA topoisomeraseIV: a primary target of fluoroquinolones. Mol.Microbiol. 13: 641 653.
56. Fisher, L. M.,, H. A. Barot,, and M. E. Cullen. 1986. DNAgyrase complex with DNA: determinants for site-specific DNA breakage. EMBO J. 5: 1411 1418.
57. Fisher, L. M.,, K. Mizuuchi,, M. H. O'Dea,, H. Ohmori,, and M. Gellert. 1981. Site-specific interaction of DNA gyrase with DNA. Proc. Natl. Acad. Sci. USA 78: 4165 4169.
58. Fournier, B.,, X . Zhao,, T. Lu,, K. Drlica,, and D. Hooper. 2000. Selective targeting of topoisomerase IV and DNAgyrase in Staphylococcus aureus: different patterns of quinolone-induced inhibition of DNA synthesis. Antimicrob.Agents Chemother. 44: 2160 2165.
59. Franco, R.,, and K. Drlica. 1988. DNA gyrase on the bacterial chromosome: oxolinic acid-induced DNA cleavage in the dnaA-gyrB region. J . Mol. Biol. 201: 229 233.
60. Fraser, C.,, S. Norris,, G. Weinstock,, O. White,, G. Sutton,, R. Dodson,, M. Gwinn,, E. Hickey,, R. Clayton,, K. Ketchum,, E. Sodergren,, J. Hardham,, M. McLeod,, S. Alzberg,, J. Peterson,, H. Khalak,, D. Richardson,, J. Howell,, M. Chidambaram,, T. Utterback,, L. McDonald,, P. Artiach,, C. Bowman,, M. Cotton,, C. Fujii,, S. Garland,, B. Hatch,, D. Horst,, K. Roberts,, M. Sandusky,, J. Weidman,, H. Smith,, and J. Venter. 1998. Complete genome sequence of Treponema pallidum, the syphilis spirochete. Science 281: 375 388.
61. Friedman, S. M.,, T. Lu,, and K. Drlica. 2001. A mutation in the DNA gyrase A gene of Escherichia coli that expands the quinolone-resistance-determining region. Antimicrob.Agents Chemother. 45: 2378 2380.
62. Fukuda, H.,, and K. Hiramatsu. 1999. Primary targets of fluoroquinolonesin Streptococcus pneumoniae . Antimicrob.Agents Chemother. 43: 410 412.
63. Fukuda, H.,, R. Kishi,, M. Takei,, and M. Hosaka. 2001. Contributions of the 8-methoxy group of gatifloxacin to resistance selectivity, target preference, and antibacterial activity against Streptococcus pneumoniae . Antimicrob.Agents Chemother. 45: 1649 1653.
64. Gellert, M.,, M. H. O'Dea,, T. Itoh,, and J.-I. Tomizawa. 1976. Novobiocin and coumermycin inhibit DNA supercoiling catalyzed by DNA gyrase. Proc. Natl. Acad. Sci. USA 73: 4474 4478.
65. Gellert, M.,, M. H. O'Dea,, K. Mizuuchi,, and H. Nash. 1976. DNA gyrase: an enzyme that introduces superhelical turns into DNA. Proc. Natl. Acad. Sci. USA 73: 3872 3876.
66. Gmuender, H.,, K. Kuratli,, K. DiPadova,, C. P. Gray,, W. Keck,, and S. Evers. 2001. Gene expression changes triggered by exposure of Haemophilus influenzae to novobiocin orciprofloxacin: combined transcription and translation analysis. Genome Res. 11: 28 42.
67. Goldman, J . D.,, D. G. White,, and S. V. Levy. 1996. Multipleantibiotic resistance (mar) locus protects Escherichia coli from rapid cell killing by fluoroquinolones. Antimicrob.Agents Chemother. 40: 1266 1269.
68. Goldstein, E.,, and K. Drlica. 1984. Regulation of bacterialDNA supercoiling: plasmid linking number varies with growth temperature. Proc. Natl. Acad. Sci. USA 81: 4046 4050.
69. Gootz, T. D. 2001. Bactericidal assays for fluoroquinolones. Methods Mol. Biol. 95: 185 194.
70. Gootz, T. D.,, R. P. Zaniewski,, S. L. Haskell,, F. S. Kaczmarek,, and A.E. Maurice. 1999. Activities oftrovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus . Antimicrob. Agents Chemother. 43: 1845 1855.
71. Goss, W.,, W. Deitz,, and T. Cook. 1964. Mechanism ofaction of nalidixic acid on Escherichia coli . J. Bacteriol. 88: 1112 1118.
72. Goss, W.,, W. Deitz,, and T. Cook. 1965. Mechanism ofaction of nalidixic acid on Escherichia coli. II. Inhibition of deoxyribonucleic acid synthesis. J. Bacteriol. 89: 068 1074.
73. Gradelski, E.,, B. Kolek,, D. Bonner,, L. Valera,, B. Minassian,,and J . Fung-Tome. 2001. Activity of gatifloxacin and ciprofloxacin in combination with other antimicrobial agents. Int. J. Antimicrob. Agents 17: 103 107.
74. Green, M.,, J . Donch,, and J . Greenburg. 1970. Effect of inhibitors of DNA synthesis on UV-sensitive derivatives of Escherichia coli strain K-12. Mutat. Res. 9: 149 154.
75. Guillemin, I.,, V. Jarlier,, and E. Cambau. 1998. Correlation between quinolone sensitivity patterns and sequences in the A and B subunits of DNA gyrase in mycobacteria. Antimicrob. Agents Chemother. 42: 2084 2088.
76. Guillemin, I.,, W. Sougakoff,, E. Cambau,, V. Revel-Viravau,, N. Moreau,, and V. Jarlier. 1999. Purification and inhibition by quinolones of DNA gyrases from Mycobacterium avium,Mycobacterium smegmatis and Mycobacterium fortuitum by. peregrinum. Microbiology 145: 2527 2532.
77. Hallett, P.,, and A. Maxwell. 1991. Novel quinolone resistance mutations of the Escherichia coli DNA gyrase A protein; enzymaticanalysis of the mutant proteins. Antimicrob.Agents Chemother. 35: 335 340.
78. Hanafi, D.,, and L. Bossi. 2000. Activation and silencing of leu-500 promter by transcription-induced DNA supercoiling in the Salmonella chromosome. Mol. Microbiol. 37: 583 594.
79. Harmon, F.,, R. DiGate,, and S. Kowaiczykowski. 1999. RecQ helicases adn topoisomerase III comprise a novel DNA strand passage function: a conserved mechanism for control of DNA recombination. Mol. Cell 3: 611ndash; 620.
80. Heaton, V. J.,, J. E. Ambler,, and L. M. Fisher. 2000. Potentantipneumococcal activity of gemifloxacin is associated with dual targeting of gyrase and topoisomerase IV, an in vivo target preference for gyrase, and enhanced stabilization of cleavable complexes invitro. Antimicrob. AgentsChemother. 44: 3112 3117.
81. Hecht, R. M.,, and D. E. Pettijohn. 1976. Studies of DNA bound RNA molecules isolated from nucleoids of Escherichia coli . Nucleic Acids Res. 3: 767 788.
82. Heddle, J .,, T. Lu,, X. Zhao,, K. Drlica, and A. Maxwell. 2001. gyrB-225, a mutation of DNA gyrase that compensates for topoisomerase I deficiency: investigation of its low activity and quinolone hypersensitivity. J. Mol. Biol. 309: 1219 1231.
83. Heddle, J . G.,, F. Barnard,, L. Wentzell,, and A. Maxwell. 2000. The interaction of drugs with DNA gyrase: a model for the molecular basis of quinolone action. Nucleosides Nucleotides Nucleic Acids 19: 1249 1264.
84. Hiasa, H. K.,, and J. Marians. 1996. Two distinct modes of strand unlinking during theta-type DNA replication. J . Biol.Chem. 271: 21529 21535.
85. Hiasa, H.,, D. Yousef,, and K. Marians. 1996. DNA strand cleavage is required for replication fork arrest by a frozen topoisomerase-quinolone-DNA ternary complex. J. Biol.Chem. 271: 26424 26429.
86. Higgins, C. F.,, C. J . Dorman,, D. A. Stirling,, L. Waddell,, I.R. Booth,, G. May,, and E. Bremer. 1988. A physiological role for DNA supercoiling in the osmotic regulation of gene expression in S. typhimurium and E. coli . Cell 52: 569 584.
87. Holmes, V.,, and N. Cozzarelli. 2000. Closing the ring: links between SMC proteins and chromosome partitioning, condensation, and supercoiling. Proc. Natl. Acad. Sci. USA 97: 1322 1324.
88. Hong, G.,, and K. Kreuzer. 2000. An antitumor drug induced topoisomerase cleavage complex blocks a bacteriophageT4 replication fork in vivo. Mol. Cell. Biol. 20: 594 603.
89. Hsieh, L.-S.,, R. M. Burger,, and K. Drlica. 1991. Bacterial DNA supercoiling and [ATP]/[ADP]: Changes associated with a transition to anaerobic growth. J. Mol. Biol. 219: 443 450.
90. Hsieh, L.-S.,, J . Rouviere-Yaniv,, and K. Drlica. 1991. Bacterial DNA supercoiling and [ATP]/[ADP]: Changes associated with salt shock. J. Bacteriol. 173: 3914 3917.
91. Huang, W. M.,, J . Libbey,, P. VanderHoeven,, and S. X. Yu. 1998. Bipolar localization of Bacillus subtilis topoisomeraseIV, an enzyme required for chromosome segregation. Proc.Natl. Acad. Sci. USA 95: 4652 4657.
92. Ikeda, H. 1994. DNA topoisomerase-mediated illegitimate recombination. Adv. Pharmacol. 29A: 147 165.
93. Ince, D.,, and D. Hooper. 2000. Mechanisms and frequency of resistance to premafloxacin in Staphylococcus aureus: Novel mutations suggest novel drug-target interactions. Antimicrob. Agents Chemother. 44: 3344 3350.
94. Ince, D.,, and D. C. Hooper. 2001. Mechanisms and frequency of resistance to gatifloxacin in comparison to AM-1121 and ciprofloxacin in Staphylococcus aureus. Antimicrob.Agents Chemother. 45: 2755 2764.
95. Kampranis, S.,, and A. Maxwell. 1998. Conformational changes in DNA gyrase revealed by limited proteolysis. J. Biol. Chem. 273: 22606 22614.
96. Kampranis, S.,, and A. Maxwell. 1998. The DNA gyrase quinolone complex, ATP hydrolysis and the mechanism of DNA cleavage. J. Biol. Chem. 273: 22615 22626.
97. Kampranis, S.,, and A. Maxwell. 1998. Hydrolysis of ATP at only one GyrB subunit is sufficient to promote super coiling by DNA gyrase. J . Biol. Chem. 273: 26305 25309.
98. Kampranis, S. C.,, and A. Maxwell. 1996. Conversion of DNA gyrase into a conventional type II topoisomerase. Proc.Natl. Acad. Sci. USA 93: 14416 14421.
99. Kato, J.-L.,, Y. Nishimura,, R. Imamura,, H. Niki,, S. Hiraga,, and H. Suzuki. 1990. New topoisomerase essential for chromosome segregation in E. coli . Cell 63: 393 404.
100. Khodursky, A.,, and N. Cozzarelli. 1998. The mechanism of inhibition of topoisomerase IV by quinolone antibacterials. J. Biol. Chem. 273: 27668 27677.
101. Khodursky, A.,, B. Peter,, M. Schmid,, J . DeRisi,, D. Botstein,, P. Brown,, and N. Cozzarelli. 2000. Analysis of topoisomerase function in bacterial replication fork movement: use of DNA microarrays. Proc. Natl. Acad. Sci. USA 97: 9419 9424.
102. Khodursky, A. B.,, E. L. Zechiedrich,, and N. R. Cozzarelli. 1995. Topoisomerase IV is a target of quinolones in Escherichia coli . Proc. Natl. Acad. Sci. USA 92: 11801 11805.
103. Krasin, F.,, and F. Hutchinson. 1977. Repair of DNA double strand breaks in Escherichia coli, which requires recA function and the presence of a duplicate genome. J. Mol. Biol. 116: 81 98.
104. Levine, C.,, H. Hiasa,, and K. Marians. 1998. DNA gyrase and topoisomerase IV: Biochemical activities, physiological roles during chromosome replication, and drug sensitivities. Biochim. Biophys. Acta 1400: 29 43.
105. Lewin, C.,, B. Howard,, N. Ratcliffe,, and J. Smith. 1989. 4-Quinolones and the SOS response. J. Med. Microbiol. 29: 139 144.
106. Lewin, C.,, and J. Smith. 1990. DNA breakdown by the 4-quinolones and its significance. J. Med. Microbiol. 31: 65 70.
107. Li, X.,, X. Zhao,, and K. Drlica. 2002. Selection of Streptococcus pneumoniae mutants having reduced susceptibility to levofloxacin and moxifloxacin. Antimicrob. AgentsChemother. 46: 522 524.
108. Lima, C.,, J. C. Wang,, and A. Mondragon. 1994. Three dimensional structure of the 67K N-terminal fragment of E.coli DNA topoisomerase I. Nature 367: 138 146. 109.
109. Liu, L.,, and J . Wang. 1987. Supercoiling of the DNA template during transcription. Proc. Natl. Acad. Sci. USA 84: 7024 7027.
110. Lockshon, D.,, and D. R. Morris. 1985. Sites of reaction of Escherichia coli DNA gyrase on pBR322 in vivo as revealed by oxolinic acid-induced plasmid linearization. J . Mol. Biol. 181: 63 74.
111. Lu, T.,, X. Zhao,, and K. Drlica. 1999. Gatifloxacin activity against quinolone-resistant gyrase: allele-specific enhancement of bacteriostatic and bactericidal activity by the C-8-methoxygroup. Antimicrob. Agents Chemother. 43: 2969 2974.
112. Manes, S. H.,, G. J . Pruss,, and K. Drlica. 1983. Inhibition of RNA synthesis by oxolinic acid is unrelated to average DNA supercoiling. J. Bacteriol. 155: 420 423.
113. Mao, Y .,, M. Sun,, S. Desai,, and L. Liu. 2000. SUMO-1 conjugation to topoisomerase I: a possible repair response to topoisomerase-mediated DNA damage. Proc. Natl. Acad.Sci. USA 97: 4046 4051.
114. Marians, K.,, and H. Hiasa. 1997. Mechanism of quinolone action: a drug-induced structural perturbation of the DNA precedes strand cleavage by topoisomerase IV. J . Biol.Chem. 272: 9401 9409.
115. Marshall, D.,, F. Bowe,, C. Hale,, G. Dougan,, and C. Dorman. 2000. DNA topology and adaptation of Salmonellatyphimurium to an intracellular environment. Philos. Trans.R. Soc. Lond. 355: 565 574.
116. McDaniel, L. S.,, L. H. Rogers,, and W. E. Hill. 1978. Survival of recombination-deficient mutants of Escherichiacoli during incubation with nalidixic acid. J . Bacteriol. 134: 1195 1198.
117. McEachem, F.,, and L. M. Fisher. 1989. Regulation of DNA supercoiling in Escherichia coli: genetic basis of a compensatory mutation in DNA gyrase. FEBS Lett. 253: 67 70.
118. McNairn, E.,, N. N. Bhriain,, and C. Dorman. 1995. Overexpression of the Shigella flexneri genes coding for DNA topoisomerase IV compensates for loss of DNA topoisomerase I: effect on virulence gene expression. Mol.Microbiol. 15: 507 517.
119. Menzel, R.,, and M. Gellert. 1983. Regulation of the genes for E. coli DNA gyrase: homeostatic control of DNA supercoiling. Cell 34: 105 113.
120. Mizushima, T.,, Y. Ohtsuka,, T. Miki,, and K. Sekimizu. 1994. Temperature shift-up leads to simultaneous and continuous plasmid DNA relaxation and induction of DnaK and GroEL proteins in anaerobically growing Escherichiacoli cells. FEMS Microbiol. Lett. 121: 333 336.
121. Mondragon, A.,, and R. DiGate. 1999. The structure of the Escherichia coli DNA topoisomerase III. Structure (Lond.) 7: 1373 1383.
122. MoraisCabral, J . H.,, A. P. Jackson,, C. V. Smith,, N. Shikotra,, A. Maxwell,, and R. C. Liddington. 1997. Crystalstructure of the breakage-reunion domain of DNA gyrase. Nature 388: 903 906.
123. Moreau, N. J .,, H. Robaux,, L. Baron,, and X. Tabary. 1990. Inhibitory effects of quinolones on pro- and eukaryotic DNA topoisomerases I and II. Antimicrob. AgentsChemother. 34: 1955 1960.
124. Morris, J .,, X.-S. Pan,, and L. M. Fisher. 2002. Grepafloxacin, a dimethyl derivative of ciprofloxacin, acts preferentially through gyrase in Streptococcus pneumoniae: role of the C-5 group in target specificity. Antimicrob.Agents Chemother. 46: 582 585.
125. Morrison, A.,, and N. R. Cozzarelli. 1979. Site-specific cleavage of DNA by E. coli DNA gyrase. Cell 17: 175 184.
126. Morrissey, L.,, and J. George. 1999. Activities of fluoroquinolones against Streptococcus pneumoniae type II topoisomerases purified as recombinant proteins. Antimicrob.Agents Chemother. 43: 2570 2585.
127. Morrissey, I.,, and J. George. 2000. Bactericial activity of gemifloxacin and other quinolones against Streptococcuspneumoniae . J. Antimicrob. Chemother. 45( Suppl. SI): 107 110.
128. Ng, E. Y.,, M. Trucksis,, and D. C. Hooper. 1996. Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus . Antimicrob.Agents Chemother. 40: 1881 1888.
129. O'Connor, M. B.,, and M. H. Malamy. 1985. Mapping of DNA gyrase cleavage sites in vivo. Oxolinic acid induced cleavages in plasmid pBR322. J . Mol. Biol. 181: 545 550.
130. Onodera, Y.,, Y. Uchida,, M. Tanaka,, and K. Sato. 1999. Dual inhibitory activity of sitafloxacin (DU-6859a) against DNA gyrase and topoisomerase IV of Streptococcus pneumoniae . J. Antimicrob. Chemother. 44: 533 536.
131. Oram, M.,, and M. Fisher. 1991. 4-quinolone resistance mutations in the DNA gyrase of Escherichia coli clinical isolates identified by using the polymerase chain reaction. Antimicrob. Agents Chemother. 35: 387 389.
132. Pan, X .,, and L. M. Fisher. 1997. Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones. Antimicrob. Agents Chemother. 41: 471 474.
133. Pan, X .,, and L. M. Fisher. 1998. DNA gyrase and topoisomeraseIV are dual targets of clinafloxacin action in Streptococcus pneumoniae . Antimicrob. Agents Chemother. 42: 2810 2816.
134. Pan, X.-S.,, J . Ambler,, S. Mehtar,, and L. M. Fisher. 1996. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae . Antimicrob. Agents Chemother. 40: 2321 2326.
135. Pan, X.-S.,, and L. M. Fisher. 1999. Streptococcus pneumoniae DNA gyrase and topoisomerase IV: overexpression, purification, and differential inhibition by fluoroquinolones. Antimicrob. Agents Chemother. 43: 1129 1136.
136. Pan, X.-S.,, G. Yague,, and L. M. Fisher. 2001. Quinolone resistance mutations in Streptococcus pneumoniae GyrA and ParC proteins: mechanistic insights into quinolone action from enzymatic analysis, intracellular levels, and phenotypes of wild-type and mutant proteins. Antimicrob. AgentsChemother. 45: 3140 3147.
137. Pato, M. L.,, M. Karlock,, C. Wall,, and N. P. Higgins. 1995. Characterization of Mu prophage lacking the central strong gyrase binding site: localization of the block in replication. J. Bacteriol. 177: 5937 5942.
138. Pestova, E.,, R. Beyer,, N. P. Cianciotto,, G. A. Noskin,, and L.R. Peterson. 1999. Contribution of topoisomerase IV andDNA gyrase mutations in Streptococcus pneumoniae to resistance to novel fluoroquinolones. Antimicrob. AgentsChemother. 43: 2000 2004.
139. Pestova, E.,, J . Millichap,, G. Noskin,, and L. Peterson. 2000. Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones. J. Antimicrob. Chemother. 45: 583 590.
140. Piddock, L.,, and R. Walters. 1992. Bactericidal activities of five quinolones for Escherichia coli strains with mutations in genes encoding the SOS response or cell division. Antimicrob.Agents Chemother. 36: 819 825.
141. Postow, L.,, N. Crisona,, B. Peter,, C. Hardy,, and N. Cozzarelli. 2001. Topological challenges to DNA replication: conformations at the fork. Proc. Natl Acad. Sci. USA 98: 8219 8226.
142. Pouliot, J .,, K. Yao,, C. Robertson,, and H. Nash. 1999. Yeast gene for a Tyr-DNA phosphodiesterase that repairs topoisomerase I complexes. Science 286: 552 555.
143. Pruss, G.,, and K. Drlica. 1986. Topoisomerase I mutants: the gene on pBR322 that encodes resistance to tetracycline affects plasmid DNA supercoiling. Proc. Natl. Acad. Sci.USA 83: 8952 8956.
144. Pruss, G. J . 1985. DNA Topoisomerase I mutants: increased heterogeneity in linking number and other replicon-dependent changes in DNA supercoiling. J. Mol. Biol. 185: 51 63.
145. Pruss, G. J .,, S. H. Manes,, and K. Drlica. 1982. Escherichia coli DNA topoisomerase I mutants: increased supercoiling is corrected by mutations near gyrase genes. Cell 31: 35 42.
146. Ratcliffe, N. T.,, and J . T. Smith. 1984. Ciprofloxacin and ofloxacin exhibit a rifampicin-resistant bactericidal mechanism not detectable in other 4-quinolone antibacterial agents. J. Pharm. Pharmacol. 36: 59P.
147. Reece, R.,, and A. Maxwell. 1991. DNA gyrase: structure and function. Crit. Rev. Biochem. Mol. Biol. 26: 335 375.
148. Sawitzke, J. A.,, and S. Austin. 2000. Suppression of chromosome segregation defects of Escherichia coli muk mutants by mutations in topoisomerase I. Proc. Natl. Acad. Sci. USA 97: 1671 1676.
149. Schofield, M. A.,, R. Agbunag,, M. Michaels,, and J . Miller. 1992. Cloning and sequencing of Escherichia coli mutR shows its identity to topB, encoding topoisomerase III. J. Bacteriol. 1774: 5168 5170.
150. Sindelar, G.,, X . Zhao,, A. Liew,, Y. Dong,, J . Zhou,, J. Domagala,,and K. Drlica. 2000. Mutant prevention concentration as a measure of fluoroquinolone potency against mycobacteria. Antimicrob. Agents Chemother. 44: 3337 3343.
151. Sinden, R. R.,, J . O. Carlson,, and D. E. Pettijohn. 1980. Torsional tension in the DNA double helix measured with trimethylpsoralen in living E. coli cells. Cell 21: 773 783.
152. Smith, J . T.,, and C. S. Lewin,. 1988. Chemistry and mechanisms of action of the quinolone antibacterials, p. 23 82. In V. T. Andriole (ed.), The Quinolones. Academic Press, San Diego, Calif..
153. Snyder, M.,, and K. Drlica. 1979. DNA gyrase on the bacterial chromosome: DNA cleavage induced by oxolinic acid. J. Mol. Biol. 131: 287 302.
154. Soussy, C.,, J. Wolfson,, E. Ng,, and D. Hooper. 1993. Limitations of plasmid complementation test for determination of quinolone resistance due to changes in gyrase A protein and identification of conditional quinolone resistance locus. Antimicrob. Agents Chemother. 37: 2588 2592.
155. Sreedharan, S.,, M. Oram,, B. Jensen,, L. Peterson, and L,Fisher. 1990. DNA gyrase gyrA mutations in ciprofloxacin resistant strains of Staphylococcus aureus: close similarity with quinolone resistance mutations in Escherichia coli . J.Bacteriol. 172: 7260 7262.
156. Srivenugopal, K.,, D. Lockshon,, and D. Morris. 1984. Escherichia coli DNA topoisomerase III: purification and characterization of a new type I enzyme. Biochemistry 23: 1899 1906.
157. Staczek, P.,, and N. P. Higgins. 1998. Gyrase and topo IVmodulate chromosome domain size in vivo . Mol. Microbiol. 29: 1435 1448.
158. Steck, T. R.,, and K. Drlica. 1984. Bacterial chromosome segregation: evidence for DNA gyrase involvement in decatenation. Cell 36: 1081 1088.
159. Steck, T. R.,, G. J . Pruss,, S. H. Manes,, L. Burg,, and K. Drlica. 1984. DNA supercoiling in gyrase mutants. J. Bacteriol. 158: 397 403.
160. Tabary, X .,, N. Moreau,, C. Dureuil,, and F. LeGoffic. 1987. Effect of DNA gyrase inhibitors pefloxacin, five other quinolones, novobiocin, and chlorobiocin on Escherichiacoli topoisomerase I. Antimicrob. Agents Chemother. 31: 1925 1928.
161. Tomb, J .,, O. White,, A. Kerlavage,, R. Clayton,, G. Sutton,, R. Fleischmann,, K. Ketchum,, H. Klenk,, S. Gill,, B. Dougherty,, K. Nelson,, J. Quackenbush,, L. Zhou,, E. Kirkness,, S. Peterson,, B. Loftus,, D. Richardson,, R. Dodson,, H. Khalak,, A. Glodek,, K. McKenney,, L. Fitzegerald,, N. Lee,, M. Adams,, and J. Venter. 1997. The complete genome sequence of the gastric pathogen Helicobacter pylori . Nature 388: 539 547.
162. Tse-Dinh, Y. 2000. Increased sensitivity to oxidative challenges associated with top A deletion in Escherichia coli . J.Bacteriol. 182: 829 832.
163. Tse-Dinh, Y.-C. 1985. Regulation of the Eschericia coli DNA topoisomerase I gene by DNA supercoiling. Nucleic Acids Res. 13: 4751 4763.
164. Tse-Dinh, Y.-C.,, H. Qi,, and R. Menzel. 1997. DNA supercoiling and bacterial adaptation: thermotolerance and thermoresistance. Trends Microbiol. 5: 323 326.
165. Wang, J.-Y.,, and M. Syvanen. 1992. DNA twist as a transcriptional sensor for environmental changes. Mol.Microbiol. 6: 1861 1866.
166. Wang, J . C. 1971. Interaction between DNA and an Escherichia coli protein. J . Mol. Biol. 55: 523 533.
167. Wang, J . C. 1998. Moving one DNA double helix through another by a type II DNA topoisomerase: the story of a simple molecular machine. Q. Rev. Biophys. 31: 107 144.
168. Weinstein-Fischer, D.,, M. Elgrably-Weiss,, and S. Altuvia, 2000. Escherichia coli response to hydrogen peroxide: a role for DNA supercoiling, topoisomerase I, and Fis. Mol.Microbiol. 35: 1413 1420.
169. Wentzell, L.,, and A. Maxwell. 2000. The complex of DNAgyrase and quinolone drugs on DNA forms a barrier to theT7 DNA polymerase replication complex. J. Mol. Biol. 304: 779 791.
170. Whoriskey, S.,, M. Scholfield,, and J . Miller. 1991. Isolation and characterization of Escherichia coli mutants with altered rates of deletion formation. Genetics 127: 21 30.
171. Wigley, D. B.,, G. J . Davies,, E. J . Dodson,, A. Maxwell,, and D. Dodson. 1991. Crystal structure of an N-terminal fragment of the DNA gyrase B protein. Nature 351: 624 629.
172. Williams, N.,, A. Howells,, and A. Maxwell. 2001. Locking the ATP-operated clamp of DNA gyrase: probing the mechanism of strand passage. J. Mol. Biol. 306: 969 984.
173. Williams, N. L.,, and A. Maxwell. 1999. Locking the DNA gate of DNA gyrase: investigating the effects on DNA cleavage and ATP hydrolysis. Biochemistry 38: 14157 14164.
174. Willmott, C. J . R.,, S. E. Critchlow,, I. C. Eperon,, and A. Maxwell. 1994. The complex of DNA gyrase and quinolone drugs with DNA forms a barrier to transcription by RNApolymerase. J. Mol. Biol. 242: 351 363.
175. Willmott, C. J . R.,, and A. Maxwell. 1993. A single point mutation in the DNA gyrase A protein greatly reduces binding of fluoroquinolones to the gyrase-DNA complex. Antimicrob. Agents Chemother. 37: 126 127.
176. Wolfson, J . S.,, D. C. Hooper,, D. J . Shih,, G. L. McHugh,, and M. N. Swartz. 1989. Isolation and characterization of an Escherichia coli strain exhibiting partial tolerance to quinolones. Antimicrob. Agents Chemother. 33: 705 709.
177. Wu, H.-Y.,, S.-H. Shyy,, J . C. Wang,, and L. F. Liu. 1988. Transcription generates positively and negatively supercoiled domains in the template. Cell 53: 433 440.
178. Wu, L.,, and I. Hickson. 2001. RecQ helicases and topoisomerases:components of a conserved complex for the regulationof genetic recombination. CMLS Cell. Mol. Life Sci. 58: 894 901.
179. Yague, G.,, J . Morris,, X.-S. Pan,, K. Gould,, and L. M. Fisher. 2002. Cleavable-complex formation by wild-type and quinolone-resistant Streptococcus pneumoniae type II topoisomerases mediated by gemifloxacin and other fluoroquinolones. Antimicrob. Agents Chemother. 46: 413 419.
180. Yang, S.-W.,, A. B. Burgin,, B. N. Huizenga,, C. A. Robertson,, K. C. Yao,, and H. A. Nash. 1996. A eukaryotic enzyme that can disjoin dead-end covalent complexes between DNA and type I topoisomerases. Proc. Natl. Acad.Sci. USA 93: 11534 11539.
181. Yang, Y .,, and G. Ames. 1988. DNA gyrase binds to the family of prokaryotic repetitive extragenic palindromicsequences. Proc. Natl. Acad. Sci. USA 85: 8850 8854.
182. Yang, Y .,, and G. Ames,. 1990. The family of repetitive extragenic palindromic sequences: interaction with DNA gyrase and histonelike protein HU, p. 211 225. In K. Drlica, and M. Riley (ed.), The Bacterial Chromosome. American Society for Microbiology, Washington, D.C..
183. Yoshida, H.,, M. Bogaki,, M. Nakamura,, and S. Nakamura. 1990. Quinolone resistance-determining region in the DNAgyrase gyrA gene of Escherichia coli . Antimicrob. AgentsChemother. 34: 1271 1272.
184. Yoshida, H.,, M. Bogaki,, M. Nakamura,, L. Yamanaka,, and S. Nakamura. 1991. Quinolone resistance-determining region in the DNA gyrase gyrB gene of Escherichia coli . Antimicrob. Agents Chemother. 35: 1647 1650.
185. Yoshida, H.,, M. Nakamura,, M. Bogaki,, H. Ito,, T. Kojima,, H. Hattori,, and S. Nakamura. 1993. Mechanism of action of quinolones against Escherichia coli DNA gyrase. Antimicrob. Agents Chemother. 37: 839 845.
186. Zechiedrich, E. L.,, A. Khodursky,, S. Bachellier,, R. Schneider,, D. Chen,, D. Lilley,, and N. Cozzarelli. 2000. Roles of topoisomerases in maintaining steady-state DNA supercoiling in Escherichia coli . J. Biol. Chem. 275: 8103 8113.
187. Zhao, B.-Y.,, R. Pine,, J . Domagala,, and K. Drlica. 1999. Fluoroquinolone action against clinical isolates of Mycobacterium tuberculosis: effects of a C8-methoxyl group on survival in liquid media and in human macrophages. Antimicrob. Agents Chemother. 43: 661 666.
188. Zhao, X.,, J.-Y. Wang,, C. Xu,, Y. Dong,, J . Zhou,, J . Domagala,, and K. Drlica. 1998. Killing of Staphylococcusaureus by C-8-methoxy fluoroquinolones. Antimicrob.Agents Chemother. 42: 956 958.
189. Zhao, X .,, C. Xu,, J. Domagala,, and K. Drlica. 1997. DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance. Proc. Natl. Acad. Sci. USA 94: 13991 13996.
190. Zhu, Q.,, P. Pongpech,, and R. DiGate. 2001. Type I topoisomerase activity is required for proper chromosomal segregation in Escherichia coli . Proc. Natl. Acad. Sci. USA 98: 9766 9771.

Tables

Generic image for table
Table 1

Inhibition of purified topoisomerase activity by fluoroquinolones

Citation: Drlica K, Hooper D. 2003. Mechanisms of Quinolone Action, p 19-40. In Hooper D, Rubinstein E (ed), Quinolone Antimicrobial Agents, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555817817.ch2
Generic image for table
Table 2

Primary fluoroquinolone targets defined genetically in

Citation: Drlica K, Hooper D. 2003. Mechanisms of Quinolone Action, p 19-40. In Hooper D, Rubinstein E (ed), Quinolone Antimicrobial Agents, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555817817.ch2

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error